Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Intensive Salvage Therapy Followed by Enasidenib for Patients With AML Harboring Mutations in IDH2 Who Have Failed or Been Refractory to One Prior Line of Therapy

NCT03881735 is registered in ClinicalTrials.gov with Roswell Park Cancer Institute as lead sponsor.

NCT NCT03881735
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03881735 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Intensive Salvage Therapy Followed by Enasidenib for Patients With AML Harboring Mutations in IDH2 Who Have Failed or Been Refractory to One Prior Line of Therapy
Lead sponsor
Roswell Park Cancer Institute
Phase
Phase 2
Overall status
Withdrawn
Start date
December 2, 2019
Completion date
November 19, 2022
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

blasts under 5 percent of peripheral blood white cells, bone marrow blasts decreased by 50 percent or more compared to pretreatment level, idh2 gene mutation, recurrent acute myeloid leukemia, refractory acute myeloid leukemia